- Home
- HOOK vs NKGN Comparison
HOOK vs NKGN Comparison
Compare HOOK & NKGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- NKGN
- Stock Information
- Founded
- HOOK 2011
- NKGN 2017
- Country
- HOOK United States
- NKGN United States
- Employees
- HOOK N/A
- NKGN 63
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- NKGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HOOK Health Care
- NKGN Health Care
- Exchange
- HOOK Nasdaq
- NKGN Nasdaq
- Market Cap
- HOOK 25.8M
- NKGN 22.6M
- IPO Year
- HOOK 2019
- NKGN N/A
- Fundamental
- Price
- HOOK $1.98
- NKGN $0.65
- Analyst Decision
- HOOK Buy
- NKGN
- Analyst Count
- HOOK 4
- NKGN 0
- Target Price
- HOOK $23.00
- NKGN N/A
- AVG Volume (30 Days)
- HOOK 64.0K
- NKGN 573.8K
- Earning Date
- HOOK 11-14-2024
- NKGN 12-31-2024
- Dividend Yield
- HOOK N/A
- NKGN N/A
- EPS Growth
- HOOK N/A
- NKGN N/A
- EPS
- HOOK N/A
- NKGN N/A
- Revenue
- HOOK $49,999,000.00
- NKGN N/A
- Revenue This Year
- HOOK $147.52
- NKGN N/A
- Revenue Next Year
- HOOK N/A
- NKGN N/A
- P/E Ratio
- HOOK N/A
- NKGN N/A
- Revenue Growth
- HOOK 143.30
- NKGN N/A
- 52 Week Low
- HOOK $1.88
- NKGN $0.20
- 52 Week High
- HOOK $10.50
- NKGN $4.06
- Technical
- Relative Strength Index (RSI)
- HOOK 29.47
- NKGN 72.02
- Support Level
- HOOK $1.96
- NKGN $0.45
- Resistance Level
- HOOK $2.18
- NKGN $0.55
- Average True Range (ATR)
- HOOK 0.20
- NKGN 0.08
- MACD
- HOOK 0.02
- NKGN 0.02
- Stochastic Oscillator
- HOOK 19.44
- NKGN 85.80
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
About NKGN NKGen Biotech Inc.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.